


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula I



wherein

- A is C, CR₁₀ or N;
X is CR₁₁ or N;
Y is CR₇ or N with the proviso that when X is N, then Y must be CR₇;
R₁ is H, C₁-C₆alkylcarbonyl, C₁-C₆alkylcarbonyloxy or an C₁-C₆alkyl, C₁-C₆alkenyl, C₁-C₆alkynyl or cycloheteroalkyl group each optionally substituted;
R₂, R₃, R₄, R₅ and R₆ are each independently H, halogen, OH or an optionally substituted C₁-C₆alkyl group;
R₇ and R₁₁ are each independently H, halogen or an C₁-C₆alkyl, aryl, heteroaryl or C₁-C₆alkoxy group each optionally substituted;
R₈ is an C₁-C₆alkyl, aryl or heteroaryl group each optionally substituted;
R₉ is H, halogen or an C₁-C₆alkyl, C₁-C₆alkoxy, C₁-C₆alkenyl, aryl or heteroaryl group each optionally substituted;
R₁₀ is H, OH or an optionally substituted C₁-C₆alkoxy group;

m is an integer of 1, 2 or 3 with the proviso that when m is 2 then A must be C or CR₁₀;
n is 0 or an integer of 1, 2 or 3; and
---- represents a single bond or a double bond; or
a pharmaceutically acceptable salt thereof.

2. (Cancelled)


3. (Original) The compound according to claim 1 wherein R₈ is an optionally substituted phenyl group.

4. (Original) The compound according to claim 1 wherein R₂, R₃, R₄, R₅ and R₆ are H.

5. (Currently Amended) The compound according to claim [[2]] 1 wherein R₁ is H or a C₁-C₆alkyl or cycloheteroalkyl group each optionally substituted.

6. (Cancelled)

7. (Currently Amended) A method for the treatment of a disorder of the central nervous system related to or affected by the 5-HT₆ receptor in a patient in need thereof which comprises administering to said patient a therapeutically effective amount of a compound of formula I.



wherein

A is C, CR₁₀ or N;

X is CR₁₁ or N;

Y is CR₇ or N with the proviso that when X is N, then Y must be CR₇;

R₁ is H, C₁-C₆alkylcarbonyl, C₁-C₆alkylcarbonyloxy or an C₁-C₆alkyl, C₁-C₆alkenyl, C₁-C₆alkynyl or cycloheteroalkyl group each optionally substituted;

R₂, R₃, R₄, R₅ and R₆ are each independently H, halogen, OH or an optionally substituted C₁-C₆alkyl group;

R₇ and R₁₁ are each independently H, halogen or an C₁-C₆alkyl, aryl, heteroaryl or C₁-C₆alkoxy group each optionally substituted;

R₈ is an C₁-C₆alkyl, aryl or heteroaryl group each optionally substituted;

R₉ is H, halogen or an C₁-C₆alkyl, C₁-C₆alkoxy, C₁-C₆alkenyl, aryl or heteroaryl group each optionally substituted;

R₁₀ is H, OH or an optionally substituted C₁-C₆alkoxy group;

m is an integer of 1, 2 or 3 with the proviso that when m is 2 then A must be C or CR₁₀;

n is 0 or an integer of 1, 2 or 3; and

---- represents a single bond or a double bond; or

a pharmaceutically acceptable salt thereof.


8. (Original) The method according to claim 7 wherein said disorder is a motor disorder, anxiety disorder or cognitive disorder.

9. (Original) The method according to claim 7 wherein said disorder is schizophrenia or depression.

10. (Original) The method according to claim 8 wherein said cognitive disorder is a neurodegenerative disorder.

11. (Original) The method according to claim 10 wherein said neurodegenerative disorder is Alzheimer's disease or Parkinson's disease

12. (Currently Amended) A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I.



wherein

A is C, CR₁₀ or N;

X is CR₁₁ or N;

Y is CR₇ or N with the proviso that when X is N, then Y must be CR₇;

R₁ is H, C₁-C₆alkylcarbonyl, C₁-C₆alkylcarbonyloxy or an C₁-C₆alkyl, C₁-C₆alkenyl, C₁-C₆alkynyl or cycloheteroalkyl group each optionally substituted;

R₂, R₃, R₄, R₅ and R₆ are each independently H, halogen, OH or an optionally substituted C₁-C₆alkyl group;

R₇ and R₁₁ are each independently H, halogen or an C₁-C₆alkyl, aryl, heteroaryl or C₁-C₆alkoxy group each optionally substituted;

R₈ is an C₁-C₆alkyl, aryl or heteroaryl group each optionally substituted;

R₉ is H, halogen or an C₁-C₆alkyl, C₁-C₆alkoxy, C₁-C₆alkenyl, aryl or heteroaryl group each optionally substituted;

R₁₀ is H, OH or an optionally substituted C₁-C₆alkoxy group;

m is an integer of 1, 2 or 3 with the proviso that when m is 2 then A must be C or CR₁₀;

n is 0 or an integer of 1, 2 or 3; and

---- represents a single bond or a double bond; or a pharmaceutically acceptable salt thereof.

13. (Cancelled)


14. (Original) The composition according to claim 12 wherein R_8 is an optionally substituted phenyl group.

15. (Original) The composition according to claim 12 wherein R_2 , R_3 , R_4 , R_5 and R_6 are H.

16. (Currently Amended) The composition according to claim [[13]] 12 wherein R_1 is H or a C_1 - C_6 alkyl or cycloheteroalkyl group each optionally substituted.

17. (Cancelled)

18. (Currently Amended) A method for the preparation of a compound of formula I.



wherein

A is C, CR_{10} or N;

X is CR_{11} or N;

Y is CR_7 or N with the proviso that when X is N, then Y must be CR_7 ;

R_1 is C_1 - C_6 alkylcarbonyl, C_1 - C_6 alkylcarbonyloxy or an C_1 - C_6 alkyl, C_1 - C_6 alkenyl, C_1 - C_6 alkynyl or cycloheteroalkyl group each optionally substituted;

R_2 , R_3 , R_4 , R_5 and R_6 are each independently H, halogen, OH or an optionally substituted C_1 - C_6 alkyl group;

R_7 and R_{11} are each independently H, halogen or an C_1 - C_6 alkyl, aryl, heteroaryl or alkoxy group each optionally substituted;

R_8 is an C_1 - C_6 alkyl, aryl or heteroaryl group each optionally substituted;

R_9 is H, halogen or an C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkenyl, aryl or heteroaryl group each optionally substituted;


R_{10} is H, OH or an optionally substituted C_1 - C_6 alkoxy group;

m is an integer of 1, 2 or 3 with the proviso that when m is 2 then A must be C or CR_{10} ;

n is 0 or an integer of 1, 2 or 3; and

---- represents a single bond or a double bond

said method which comprises reacting a compound of formula Ia



wherein A, X, R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , m and n are as defined hereinabove for formula I with a compound R_1 -Hal wherein R_1 is as defined hereinabove for formula I and Hal is Cl, Br or I.